Hyaluronidase + Azoxime bromide (Hyaluronidasum + Azoximeri bromidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Enzymes and antiferments

Included in the formulation
АТХ:

V.03.A.X   Other medications

Pharmacodynamics:

Proteolytic enzyme agent with hyaluronidase activity. Selectively affects glycosaminoglycans: hyaluronic acid and chondroitin sulfates, which bind the connective tissue.

Depolymerization of glycosaminoglycans leads to a decrease in their viscosity, which reduces the ability to bind water and metal cations. This leads to a weakening of the intermolecular bonds of the connective tissue, therefore, hematomas dissolve, spikes are extended, joint mobility improves.

When combined with intramuscular or subcutaneous injection, accelerates and increases absorption of drugs.

Pharmacokinetics:

After intramuscular or subcutaneous injection, the maximum concentration in the blood plasma is reached after 20-25 minutes.

Penetrates through the blood-brain and placental barrier, is found in breast milk. Metabolism in the liver by hydrolysis.

The half-life is 36 hours with intramuscular injection; 45 hours - with subcutaneous injection. Elimination by the kidneys.

Indications:

It is used for the prevention and treatment of adhesions. Used in urology, gynecology, surgery, pulmonology, dermatovenereology with the aim of increasing the bioavailability of antibacterial drugs.

ICD-10

I.A15-A19.A15   Tuberculosis of respiratory organs, confirmed bacteriologically and histologically

X.J60-J70.J63   Pneumoconiosis caused by other inorganic dust

X.J80-J84.J84   Other interstitial lung diseases

X.J90-J94.J90   Pleural effusion, not elsewhere classified

XI.K65-K67.K66.0   Peritoneal adhesions

XII.L80-L99.L91.0   Keloid scar

XII.L80-L99.L94.0   Localized scleroderma [morphea]

XIII.M15-M19.M15   Polyarthrosis

XIII.M65-M68.M67.1   Another contracture of the tendon (vagina)

XIV.N30-N39.N30   Cystitis

XIV.N30-N39.N35   Urethral stricture

XIV.N40-N51.N40   Hyperplasia of the prostate

XIV.N40-N51.N41   Inflammatory diseases of the prostate

XIV.N40-N51.N48   Other diseases of the penis

XIV.N70-N77.N71   Inflammatory diseases of the uterus, except the cervix

XIV.N80-N98.N85.6   Intrauterine synechiae

XIV.N80-N98.N97   Female infertility

XIV.N99.N99.4   Postoperative adhesions in the pelvis

XIX.T08-T14.T14.0   Superficial injury of unspecified area of ​​the body

XIX.T08-T14.T14.1   Open wound of unspecified area of ​​the body

Contraindications:Acute infectious diseases, malignant neoplasms, hemoptysis and pulmonary hemorrhage, severe renal failure, vitreous hemorrhage, individual intolerance, children under 18 years of age.

Carefully:

Chronic renal failure, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Subcutaneously, in the lesions. Intramuscularly for 3000 IU. The course of treatment is 5-25 injections. Interval of administration: 3-10 days.

To increase the bioavailability, in the same place, 1500 IU each 10-15 minutes before the introduction of the main drug.

The highest daily dose: 3000 IU.

The highest single dose: 3000 IU.

Side effects:

Central and peripheral nervous system: dizziness, confusion.

The cardiovascular system: arterial hypotension.

Allergic reactions.

Overdose:

Arterial hypotension, chills, hyperthermia.

Treatment: withdrawal of the drug followed by symptomatic therapy.

Interaction:

Clinically significant interactions are not described.

Special instructions:

It is not recommended subcutaneous injection of the drug into the zone of acute infectious inflammation.

Intravenous administration is contraindicated.

Instructions
Up